Nextcure Inc (NXTC) Stock Price, Quote & News

Company Profile

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease;...

Industry: Biotechnology

Sector: Healthcare

Phone: 240 399 4900

Website: www.nextcure.com

Address:

9000 Virginia Manor Road, Suite 200, Beltsville, United States

_Volumetrix Dec. 8 at 11:47 PM

$PASG $NXTC $HTOO $GORV $MFI p

0 · Reply

MoneyGroupLLC Dec. 7 at 10:07 PM

Enter: $NXTC Calls Strike Price: $2 Expiry Date: DEC 19 2025 Buy in Price: $0.05 - $0.05 Sell Price: $0.07 Profit : +42% (Turn every $1 into $1.42) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

MoneyGroupLLC Dec. 6 at 2:11 AM

Enter: $NXTC Calls Strike Price: $2 Expiry Date: DEC 19 2025 Buy in Price: $0.05 - $0.05 Sell Price: $0.09 Profit : +83% (Turn every $1 into $1.83) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

MoneyGroupLLC Dec. 4 at 6:17 PM

Enter: $NXTC Calls Strike Price: $2 Expiry Date: DEC 19 2025 Buy in Price: $0.05 - $0.05 Sell Price: $0.11 Profit : +110% (Turn every $1 into $2.10) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

MoneyGroupLLC Dec. 3 at 11:27 AM

Enter: $NXTC Calls Strike Price: $2 Expiry Date: DEC 19 2025 Buy in Price: $0.05 - $0.05 Sell Price: $0.10 Profit : +105% (Turn every $1 into $2.05) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Stock_Catcher Dec. 1 at 2:50 AM

Money Monday Watchlist Pt. 2 $ABVE $NEGG $CDT $NXTC $ADTX New Month December. Let's Go! 📈

0 · Reply

MoneyGroupLLC Nov. 29 at 11:40 AM

Enter: $NXTC Calls Strike Price: $2 Expiry Date: DEC 19 2025 Buy in Price: $0.05 - $0.05 Sell Price: $0.08 Profit : +69% (Turn every $1 into $1.69) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

MoneyGroupLLC Nov. 27 at 11:36 AM

Enter: $NXTC Calls Strike Price: $2 Expiry Date: DEC 19 2025 Buy in Price: $0.05 - $0.05 Sell Price: $0.08 Profit : +64% (Turn every $1 into $1.64) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Stock_Catcher Nov. 26 at 2:21 AM

Money Wednesday Watchlist Pt.4 $NUKK $MIGI $NDRA $BULL $NXTC Let's Bank Tomorrow

0 · Reply

MoneyGroupLLC Nov. 26 at 1:56 AM

Enter: $NXTC Calls Strike Price: $2 Expiry Date: DEC 19 2025 Buy in Price: $0.05 - $0.05 Sell Price: $0.09 Profit : +84% (Turn every $1 into $1.84) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta

Jun 16, 2025, 10:03 AM EDT - 6 months ago

NextCure signs up to $745 million deal with China's Simcere to develop cancer drug

Jun 16, 2025, 7:05 AM EDT - 6 months ago

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

May 29, 2025, 4:05 PM EDT - 6 months ago

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

NextCure Provides Business Update and Reports First Quarter 2025 Financial Results

May 1, 2025, 4:05 PM EDT - 7 months ago

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

Dec 10, 2024, 8:05 AM EST - 1 year ago

NextCure Announces Acceptance of IND Application for LNCB74

Nov 26, 2024, 7:00 AM EST - 1 year ago

NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference

Nov 19, 2024, 8:05 AM EST - 1 year ago

Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta

Nov 7, 2024, 4:05 PM EST - 1 year ago

NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 5, 2024, 4:05 PM EST - 1 year ago

NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting

NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting

Oct 4, 2024, 9:05 AM EDT - 1 year ago

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

Dec 21, 2023, 7:05 AM EST - 2 years ago

NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury

NextCure Provides Year-End Clinical Pipeline Updates

Dec 14, 2023, 6:45 AM EST - 2 years ago

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)

Sep 26, 2023, 4:05 PM EDT - 2 years ago

NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer's Disease

$A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC$